Mi-2 antibodies

04/11/2023 - "Pathologic Features of Anti-Mi-2 Dermatomyositis."
10/06/2022 - "Anti-Mi-2 dermatomyositis with ulcerative plaques."
03/01/2022 - "Case of anti-Mi-2 antibody-positive dermatomyositis with predictable onset before the development of muscle symptoms."
01/01/2022 - "To evaluate the performance characteristics of a line immunoassay (LIA) for the detection of Mi-2 antibodies associated with dermatomyositis (DM). "
01/01/2021 - "Pathologic Features of Anti-Mi-2 Dermatomyositis."

04/20/2022 - "Anti-Mi-2 antibody-positive DM patients may present with the typical skin lesions and prominent myositis. "
02/01/2006 - "Data were compared with results for a large group of anti-Mi-2 negative patients with myositis published previously. "
07/01/1985 - "Anti-Mi-2 appears to be closely linked to DM, and is the first specific serologic marker for this form of myositis."
12/01/2023 - "A 77-year-old woman developed anti-Mi-2 DM with severe diffuse muscle weakness associated with abundant mitochondrial abnormalities at muscle biopsy, beside the typical features of inflammatory myopathy. "
03/01/2014 - "Our findings indicate that the presence of antisynthetase and anti-Mi-2 autoantibodies, juvenile DM subset, and lower disease damage strongly predict clinical improvement in patients with refractory myositis."

01/01/2019 - "Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15). "
04/01/2011 - "Anti-Mi-2 was associated with classical DM without interstitial lung disease or malignancy, whereas anti-155/140 was associated with malignancy. "
01/01/2023 - "Our study included 109 patients, 64 with anti-ARS, 28 with anti-MDA5, 9 with anti-Mi-2, and 8 with anti-TIF1-γ antibodies; 16 and 5 patients were diagnosed with a malignancy within 3 years before or after and within 4 to 10 years after their IIM onset, respectively. "
01/01/2023 - "The SIRs of malignancy within 3 years of IIM onset for each MSA were calculated as follows: 2.12 (95% confidence interval [CI] 0.98-4.35) for anti-ARS, 1.87 (95% CI 0.48-4.97) for anti-MDA5, 2.11 (95% CI 0.11-13.69) for anti-Mi-2, and 9.30 (95% CI 2.98-25.58) for anti-TIF1-γ antibodies. "
01/01/2021 - "Anti-Mi-2 autoantibodies, in contrast, are typically associated with classic DM rashes, prominent skeletal muscle weakness, better therapeutic response and prognosis, and less frequently with cancer. "

02/01/2017 - "Among patients with cancer-associated dermatomyositis, three were positive for anti-TIF1γ/α, two for anti-Mi-2, and one for anti-MJ/NXP-2. The strongest positivity of anti-TIF1γ was seen in two active forms of cancer, and this antibody was either negative or positive at low titers in the absence of cancer or in the 7-year remission Hodgkin's lymphoma. "

04/01/2011 - "Anti-Mi-2 was associated with classical DM without interstitial lung disease or malignancy, whereas anti-155/140 was associated with malignancy. "
12/01/2021 - "A Man With Recurrent Pneumonitis: A Rare Case of Interstitial Lung Disease Associated With Anti-Mi-2 Beta-Specific Dermatomyositis."
05/01/2020 - "Anti-Mi-2 antibody-positive DM patients show the typical skin lesions and myositis and are rarely associated with internal malignancy and interstitial lung disease (ILD). "
01/01/2020 - "Anti-Mi-2 antibodies are widely associated with DM cases that exhibit mainly cutaneous symptoms, such as cuticular overgrowths, Gottron's papules while being less susceptible to complications like interstitial lung disease or malignancy. "
12/01/2021 - "Anti-Mi-2 antibody-specific dermatomyositis has a lower prevalence of interstitial lung disease and has a favorable prognosis, responding well to steroids. Our patient is a 72-year old male who presented with recurrent episodes of pneumonitis, and ILD was found to have anti-Mi-2 beta-specific dermatomyositis and SLE overlap disease. "